[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fMy359xBzfgcN32ACvQmfiXrEGwr0wLCe_6RSrTApPB8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":10,"truncated":11,"activeTrials":12,"phase3Count":13,"totalEnrollment":14,"activePrograms":15,"nonDrugCount":16,"topConditions":17,"upcomingReadouts":37,"phaseBuckets":82,"rows":89},"University of Tennessee",[4,6,7,8,9],"University of Tennessee Graduate School of Medicine","University of Tennessee Medical Center","University of Tennessee, Chattanooga","University of Tennessee Cancer Institute",176,false,31,9,78306,13,106,[18,21,24,27,29,31,33,35],{"name":19,"count":20},"Obesity",8,{"name":22,"count":23},"Preeclampsia",6,{"name":25,"count":26},"Smoking Cessation",3,{"name":28,"count":26},"Pain, Postoperative",{"name":30,"count":26},"Hypertension",{"name":32,"count":26},"Cardiovascular Diseases",{"name":34,"count":26},"Heart Diseases",{"name":36,"count":26},"Pain",[38,43,48,52,57,62,67,72,77],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06433674","Enteral Zinc Supplementation in Very Low Birth Weight Infants","2025-07-01","Zinc Sulfate",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06506565","Low-Dose Ketamine Infusion During Burn Wound Care","2025-12","Ketamine",{"nctId":49,"briefTitle":50,"date":46,"intervention":51},"NCT06669650","Personalized Post-Operative Pain Management","Oxycodone",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT07133880","Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators","2025-12-01","umeclidinium 62.5 µg and vilanterol 25 µg",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT06842771","Pain with Differing Intraperitoneal Washes At the End of Laparoscopic Gynecologic Surgery","2026-02","Marcaine hydrochloride without epinephrine 0.5%",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT07465432","Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries","2027-02-28","Cefiderocol",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06907849","124I-Evuzamitide PET\u002FCT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome","2027-03","124I-evuzamitide",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT05024344","ESP Block vs Control for Pain Control Following Percutaneous Nephrolithotomy","2027-12-31","Ropivacaine 0.5% Injectable Solution",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06925152","COMFORT Trial: Complex Obstetric Management With Focused Regional Transversus Abdominis Plane Block","2028-05","Bupivicaine intervention arm",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,117,135,159,177,199,217,241,262,284,306,331,370,388,414,439,464,494,512,537,564,582,600,628,646,670,695,713,739,775,812,830,848,874,892,917,954,979,1004,1028,1052,1078,1103,1121,1139,1165,1183,1207,1225,1243,1261,1279,1297,1322,1349,1374,1398,1423,1447,1480,1504,1530,1548,1566,1591,1609,1627,1649,1674,1698,1716,1744,1762,1780,1806,1824,1842,1871,1907,1941,1959,1977,2002,2020,2045,2063,2088,2106,2133,2155,2179,2202,2226,2253,2276,2299,2323,2349],{"intervention":47,"totalTrials":91,"cells":92},1,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":115},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[],{"trials":101,"activeCount":95},[],{"trials":103,"activeCount":91,"soonestReadout":46},[104],{"nctId":44,"briefTitle":45,"status":105,"phases":106,"primaryCompletion":46,"completion":46,"start":107,"enrollment":108,"conditions":109,"interventions":113},"RECRUITING",[87],"2024-07-08",140,[110,36,111,112],"Burn","Dissociation","Opioid",[47,114],"0.9% NaCl",{"trials":116,"activeCount":95},[],{"intervention":114,"totalTrials":91,"cells":118},{"EARLY_PHASE1":119,"PHASE1":121,"PHASE2":123,"PHASE3":125,"PHASE4":127,"NA":133},{"trials":120,"activeCount":95},[],{"trials":122,"activeCount":95},[],{"trials":124,"activeCount":95},[],{"trials":126,"activeCount":95},[],{"trials":128,"activeCount":91,"soonestReadout":46},[129],{"nctId":44,"briefTitle":45,"status":105,"phases":130,"primaryCompletion":46,"completion":46,"start":107,"enrollment":108,"conditions":131,"interventions":132},[87],[110,36,111,112],[47,114],{"trials":134,"activeCount":95},[],{"intervention":51,"totalTrials":91,"cells":136},{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":157},{"trials":138,"activeCount":95},[],{"trials":140,"activeCount":95},[],{"trials":142,"activeCount":95},[],{"trials":144,"activeCount":95},[],{"trials":146,"activeCount":91,"soonestReadout":46},[147],{"nctId":49,"briefTitle":50,"status":148,"phases":149,"primaryCompletion":46,"completion":46,"start":150,"enrollment":151,"conditions":152,"interventions":155},"ACTIVE_NOT_RECRUITING",[87],"2024-09-25",208,[153,154],"Persistent Post Operative Opioid Use","Post-surgical Pain",[51,156],"Hydromorphone",{"trials":158,"activeCount":95},[],{"intervention":156,"totalTrials":91,"cells":160},{"EARLY_PHASE1":161,"PHASE1":163,"PHASE2":165,"PHASE3":167,"PHASE4":169,"NA":175},{"trials":162,"activeCount":95},[],{"trials":164,"activeCount":95},[],{"trials":166,"activeCount":95},[],{"trials":168,"activeCount":95},[],{"trials":170,"activeCount":91,"soonestReadout":46},[171],{"nctId":49,"briefTitle":50,"status":148,"phases":172,"primaryCompletion":46,"completion":46,"start":150,"enrollment":151,"conditions":173,"interventions":174},[87],[153,154],[51,156],{"trials":176,"activeCount":95},[],{"intervention":56,"totalTrials":91,"cells":178},{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":185,"PHASE4":187,"NA":197},{"trials":180,"activeCount":95},[],{"trials":182,"activeCount":95},[],{"trials":184,"activeCount":95},[],{"trials":186,"activeCount":95},[],{"trials":188,"activeCount":91,"soonestReadout":55},[189],{"nctId":53,"briefTitle":54,"status":105,"phases":190,"primaryCompletion":55,"completion":55,"start":191,"enrollment":192,"conditions":193,"interventions":195},[87],"2023-12-05",72,[194],"COPD (Chronic Obstructive Pulmonary Disease)",[56,196],"Revefenacin 175 µg, Formoterol 20 µg",{"trials":198,"activeCount":95},[],{"intervention":196,"totalTrials":91,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":209,"NA":215},{"trials":202,"activeCount":95},[],{"trials":204,"activeCount":95},[],{"trials":206,"activeCount":95},[],{"trials":208,"activeCount":95},[],{"trials":210,"activeCount":91,"soonestReadout":55},[211],{"nctId":53,"briefTitle":54,"status":105,"phases":212,"primaryCompletion":55,"completion":55,"start":191,"enrollment":192,"conditions":213,"interventions":214},[87],[194],[56,196],{"trials":216,"activeCount":95},[],{"intervention":81,"totalTrials":91,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":227,"NA":239},{"trials":220,"activeCount":95},[],{"trials":222,"activeCount":95},[],{"trials":224,"activeCount":95},[],{"trials":226,"activeCount":95},[],{"trials":228,"activeCount":91,"soonestReadout":80},[229],{"nctId":78,"briefTitle":79,"status":105,"phases":230,"primaryCompletion":80,"completion":80,"start":231,"enrollment":232,"conditions":233,"interventions":238},[87],"2025-07-15",120,[234,235,236,237],"Complex Obstetric Surgery","Perioperative Pain Management","Cesarean Delivery","Postoperative Pain Control",[81],{"trials":240,"activeCount":95},[],{"intervention":66,"totalTrials":91,"cells":242},{"EARLY_PHASE1":243,"PHASE1":245,"PHASE2":247,"PHASE3":249,"PHASE4":251,"NA":260},{"trials":244,"activeCount":95},[],{"trials":246,"activeCount":95},[],{"trials":248,"activeCount":95},[],{"trials":250,"activeCount":95},[],{"trials":252,"activeCount":91,"soonestReadout":65},[253],{"nctId":63,"briefTitle":64,"status":105,"phases":254,"primaryCompletion":65,"completion":65,"start":255,"enrollment":256,"conditions":257,"interventions":259},[87],"2026-02-16",12,[258],"Drug Clearance After Severe Burn Injury",[66],{"trials":261,"activeCount":95},[],{"intervention":61,"totalTrials":91,"cells":263},{"EARLY_PHASE1":264,"PHASE1":266,"PHASE2":268,"PHASE3":270,"PHASE4":272,"NA":282},{"trials":265,"activeCount":95},[],{"trials":267,"activeCount":95},[],{"trials":269,"activeCount":95},[],{"trials":271,"activeCount":95},[],{"trials":273,"activeCount":91,"soonestReadout":60},[274],{"nctId":58,"briefTitle":59,"status":275,"phases":276,"primaryCompletion":60,"completion":70,"start":277,"enrollment":278,"conditions":279,"interventions":281},"NOT_YET_RECRUITING",[87],"2025-03",96,[280],"Laparoscopic Adnexal Surgery",[61],{"trials":283,"activeCount":95},[],{"intervention":42,"totalTrials":91,"cells":285},{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":302,"NA":304},{"trials":287,"activeCount":95},[],{"trials":289,"activeCount":95},[],{"trials":291,"activeCount":95},[],{"trials":293,"activeCount":91,"soonestReadout":41},[294],{"nctId":39,"briefTitle":40,"status":275,"phases":295,"primaryCompletion":41,"completion":41,"start":296,"enrollment":297,"conditions":298,"interventions":301},[86],"2024-06-01",50,[299,300],"Very Low Birth Weight Infant","Nutritional Deficiency",[42],{"trials":303,"activeCount":95},[],{"trials":305,"activeCount":95},[],{"intervention":71,"totalTrials":91,"cells":307},{"EARLY_PHASE1":308,"PHASE1":310,"PHASE2":312,"PHASE3":325,"PHASE4":327,"NA":329},{"trials":309,"activeCount":95},[],{"trials":311,"activeCount":95},[],{"trials":313,"activeCount":91,"soonestReadout":70},[314],{"nctId":68,"briefTitle":69,"status":315,"phases":316,"primaryCompletion":70,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":324},"ENROLLING_BY_INVITATION",[85],"2027-05","2025-05",40,[321,322,323],"Lumbar Spinal Stenosis","Carpal Tunnel Syndrome (CTS)","Cardiac Amyloidosis",[71],{"trials":326,"activeCount":95},[],{"trials":328,"activeCount":95},[],{"trials":330,"activeCount":95},[],{"intervention":332,"totalTrials":333,"cells":334},"Dexamethasone",2,{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":356,"PHASE4":358,"NA":360},{"trials":336,"activeCount":95},[],{"trials":338,"activeCount":95},[],{"trials":340,"activeCount":95},[341],{"nctId":342,"briefTitle":343,"status":344,"phases":345,"completion":346,"start":347,"conditions":348,"interventions":350},"NCT00003007","Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma","COMPLETED",[85],"2004-01","1996-07",[349],"Multiple Myeloma and Plasma Cell Neoplasm",[351,352,353,354,355],"recombinant interferon alfa","sargramostim","cyclophosphamide","dexamethasone","melphalan",{"trials":357,"activeCount":95},[],{"trials":359,"activeCount":95},[],{"trials":361,"activeCount":91,"soonestReadout":75},[362],{"nctId":73,"briefTitle":74,"status":105,"phases":363,"primaryCompletion":75,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":369},[88],"2028-06-30","2021-08-09",128,[368],"Nephrolithotomy, Percutaneous",[76,332],{"intervention":76,"totalTrials":91,"cells":371},{"EARLY_PHASE1":372,"PHASE1":374,"PHASE2":376,"PHASE3":378,"PHASE4":380,"NA":382},{"trials":373,"activeCount":95},[],{"trials":375,"activeCount":95},[],{"trials":377,"activeCount":95},[],{"trials":379,"activeCount":95},[],{"trials":381,"activeCount":95},[],{"trials":383,"activeCount":91,"soonestReadout":75},[384],{"nctId":73,"briefTitle":74,"status":105,"phases":385,"primaryCompletion":75,"completion":364,"start":365,"enrollment":366,"conditions":386,"interventions":387},[88],[368],[76,332],{"intervention":389,"totalTrials":91,"cells":390},"intravenous midazolam",{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":395,"PHASE3":397,"PHASE4":399,"NA":412},{"trials":392,"activeCount":95},[],{"trials":394,"activeCount":95},[],{"trials":396,"activeCount":95},[],{"trials":398,"activeCount":95},[],{"trials":400,"activeCount":95},[401],{"nctId":402,"briefTitle":403,"status":344,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":411},"NCT06449365","Comparison of Intravenous V\u002FS Nasal Atomizer Delivery of Midazolam for Conscious Sedation for No-scalpel Vasectomy",[87],"2020-08-07","2017-10-22",35,[409,410],"Vasectomy","Sedation",[389],{"trials":413,"activeCount":95},[],{"intervention":415,"totalTrials":91,"cells":416},"Dexmedetomidine",{"EARLY_PHASE1":417,"PHASE1":419,"PHASE2":421,"PHASE3":423,"PHASE4":425,"NA":437},{"trials":418,"activeCount":95},[],{"trials":420,"activeCount":95},[],{"trials":422,"activeCount":95},[],{"trials":424,"activeCount":95},[],{"trials":426,"activeCount":95},[427],{"nctId":428,"briefTitle":429,"status":344,"phases":430,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":436},"NCT02548923","Dexmedetomidine Versus Propofol for Prolonged Sedation in Critically Ill Trauma and Surgical Patients",[87],"2015-04","2014-11",57,[435],"Delirium",[415],{"trials":438,"activeCount":95},[],{"intervention":440,"totalTrials":91,"cells":441},"Propranolol",{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":450,"NA":462},{"trials":443,"activeCount":95},[],{"trials":445,"activeCount":95},[],{"trials":447,"activeCount":95},[],{"trials":449,"activeCount":95},[],{"trials":451,"activeCount":95},[452],{"nctId":453,"briefTitle":454,"status":344,"phases":455,"primaryCompletion":456,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":461},"NCT02957331","Beta Blockade in in Traumatic Brain Injury",[87],"2018-05","2016-01",26,[460],"Brain Injuries, Traumatic",[440],{"trials":463,"activeCount":95},[],{"intervention":465,"totalTrials":91,"cells":466},"Oliceridine",{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":492},{"trials":468,"activeCount":95},[],{"trials":470,"activeCount":95},[],{"trials":472,"activeCount":95},[],{"trials":474,"activeCount":95},[],{"trials":476,"activeCount":95},[477],{"nctId":478,"briefTitle":479,"status":344,"phases":480,"primaryCompletion":481,"completion":482,"start":483,"enrollment":12,"conditions":484,"interventions":490},"NCT05465226","Oliceridine in Patients With Acute Burn Injuries",[87],"2023-09-30","2023-10-24","2023-04-01",[485,486,487,488,489],"Acute Pain","Burns","Adverse Drug Event","Respiratory Depression","Nausea and Vomiting, Postoperative",[465,491],"Historical opioid use",{"trials":493,"activeCount":95},[],{"intervention":491,"totalTrials":91,"cells":495},{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":504,"NA":510},{"trials":497,"activeCount":95},[],{"trials":499,"activeCount":95},[],{"trials":501,"activeCount":95},[],{"trials":503,"activeCount":95},[],{"trials":505,"activeCount":95},[506],{"nctId":478,"briefTitle":479,"status":344,"phases":507,"primaryCompletion":481,"completion":482,"start":483,"enrollment":12,"conditions":508,"interventions":509},[87],[485,486,487,488,489],[465,491],{"trials":511,"activeCount":95},[],{"intervention":513,"totalTrials":91,"cells":514},"Quetiapine",{"EARLY_PHASE1":515,"PHASE1":517,"PHASE2":519,"PHASE3":521,"PHASE4":523,"NA":535},{"trials":516,"activeCount":95},[],{"trials":518,"activeCount":95},[],{"trials":520,"activeCount":95},[],{"trials":522,"activeCount":95},[],{"trials":524,"activeCount":95},[525],{"nctId":526,"briefTitle":527,"status":344,"phases":528,"primaryCompletion":529,"completion":529,"start":530,"enrollment":531,"conditions":532,"interventions":534},"NCT02612948","Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients",[87],"2014-06","2013-11",82,[533],"Psychomotor Agitation",[513],{"trials":536,"activeCount":95},[],{"intervention":538,"totalTrials":91,"cells":539},"intranasal ketamine",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":548,"NA":562},{"trials":541,"activeCount":95},[],{"trials":543,"activeCount":95},[],{"trials":545,"activeCount":95},[],{"trials":547,"activeCount":95},[],{"trials":549,"activeCount":95},[550],{"nctId":551,"briefTitle":552,"status":344,"phases":553,"primaryCompletion":554,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":559},"NCT02635282","IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D",[87],"2017-03-23","2016-08",19,[558,36],"Abscess",[538,560,561],"intranasal fentanyl","intranasal midazolam",{"trials":563,"activeCount":95},[],{"intervention":560,"totalTrials":91,"cells":565},{"EARLY_PHASE1":566,"PHASE1":568,"PHASE2":570,"PHASE3":572,"PHASE4":574,"NA":580},{"trials":567,"activeCount":95},[],{"trials":569,"activeCount":95},[],{"trials":571,"activeCount":95},[],{"trials":573,"activeCount":95},[],{"trials":575,"activeCount":95},[576],{"nctId":551,"briefTitle":552,"status":344,"phases":577,"primaryCompletion":554,"completion":554,"start":555,"enrollment":556,"conditions":578,"interventions":579},[87],[558,36],[538,560,561],{"trials":581,"activeCount":95},[],{"intervention":561,"totalTrials":91,"cells":583},{"EARLY_PHASE1":584,"PHASE1":586,"PHASE2":588,"PHASE3":590,"PHASE4":592,"NA":598},{"trials":585,"activeCount":95},[],{"trials":587,"activeCount":95},[],{"trials":589,"activeCount":95},[],{"trials":591,"activeCount":95},[],{"trials":593,"activeCount":95},[594],{"nctId":551,"briefTitle":552,"status":344,"phases":595,"primaryCompletion":554,"completion":554,"start":555,"enrollment":556,"conditions":596,"interventions":597},[87],[558,36],[538,560,561],{"trials":599,"activeCount":95},[],{"intervention":601,"totalTrials":91,"cells":602},"Revefenacin",{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":609,"PHASE4":611,"NA":626},{"trials":604,"activeCount":95},[],{"trials":606,"activeCount":95},[],{"trials":608,"activeCount":95},[],{"trials":610,"activeCount":95},[],{"trials":612,"activeCount":95},[613],{"nctId":614,"briefTitle":615,"status":616,"phases":617,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":624},"NCT04655170","Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD","UNKNOWN",[87],"2023-01-30","2023-03-30","2020-12-09",60,[623],"COPD Exacerbation",[601,625],"Albuterol Inhalation Aerosol",{"trials":627,"activeCount":95},[],{"intervention":625,"totalTrials":91,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":636,"PHASE4":638,"NA":644},{"trials":631,"activeCount":95},[],{"trials":633,"activeCount":95},[],{"trials":635,"activeCount":95},[],{"trials":637,"activeCount":95},[],{"trials":639,"activeCount":95},[640],{"nctId":614,"briefTitle":615,"status":616,"phases":641,"primaryCompletion":618,"completion":619,"start":620,"enrollment":621,"conditions":642,"interventions":643},[87],[623],[601,625],{"trials":645,"activeCount":95},[],{"intervention":647,"totalTrials":91,"cells":648},"Vancomycin Powder",{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":655,"PHASE4":657,"NA":668},{"trials":650,"activeCount":95},[],{"trials":652,"activeCount":95},[],{"trials":654,"activeCount":95},[],{"trials":656,"activeCount":95},[],{"trials":658,"activeCount":95},[659],{"nctId":660,"briefTitle":661,"status":616,"phases":662,"primaryCompletion":663,"completion":663,"start":664,"enrollment":108,"conditions":665,"interventions":667},"NCT01977989","Vancomycin in Spine Surgery",[87],"2015-10","2013-10",[666],"Wound Infection",[647],{"trials":669,"activeCount":95},[],{"intervention":671,"totalTrials":91,"cells":672},"Aspirin 81 mg Enteric Coated Tab - 1",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":679,"PHASE4":681,"NA":693},{"trials":674,"activeCount":95},[],{"trials":676,"activeCount":95},[],{"trials":678,"activeCount":95},[],{"trials":680,"activeCount":95},[],{"trials":682,"activeCount":95},[683],{"nctId":684,"briefTitle":685,"status":686,"phases":687,"primaryCompletion":688,"completion":688,"start":689,"enrollment":95,"conditions":690,"interventions":691},"NCT04158830","Aspirin (ASA) Therapy and Preeclampsia Prevention","WITHDRAWN",[87],"2021-11-30","2020-06-01",[22],[671,692],"Aspirin 81 mg Enteric Coated Tab - 2",{"trials":694,"activeCount":95},[],{"intervention":692,"totalTrials":91,"cells":696},{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":703,"PHASE4":705,"NA":711},{"trials":698,"activeCount":95},[],{"trials":700,"activeCount":95},[],{"trials":702,"activeCount":95},[],{"trials":704,"activeCount":95},[],{"trials":706,"activeCount":95},[707],{"nctId":684,"briefTitle":685,"status":686,"phases":708,"primaryCompletion":688,"completion":688,"start":689,"enrollment":95,"conditions":709,"interventions":710},[87],[22],[671,692],{"trials":712,"activeCount":95},[],{"intervention":714,"totalTrials":91,"cells":715},"oral cromolyn sodium",{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":722,"PHASE4":724,"NA":737},{"trials":717,"activeCount":95},[],{"trials":719,"activeCount":95},[],{"trials":721,"activeCount":95},[],{"trials":723,"activeCount":95},[],{"trials":725,"activeCount":95},[726],{"nctId":727,"briefTitle":728,"status":344,"phases":729,"primaryCompletion":730,"completion":731,"start":732,"enrollment":733,"conditions":734,"interventions":736},"NCT02371941","Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis",[87],"2017-07","2017-12","2014-12",16,[735],"Eosinophilic Esophagitis",[714],{"trials":738,"activeCount":95},[],{"intervention":740,"totalTrials":333,"cells":741},"Acetaminophen",{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":755,"PHASE3":757,"PHASE4":771,"NA":773},{"trials":743,"activeCount":95},[],{"trials":745,"activeCount":95},[746],{"nctId":747,"briefTitle":748,"status":616,"phases":749,"primaryCompletion":731,"completion":731,"start":750,"enrollment":751,"conditions":752,"interventions":754},"NCT02694653","Preoperative Cesarean Section Intravenous Acetaminophen and Postoperative Pain Control",[84],"2014-10",200,[753],"Complications; Cesarean Section",[740],{"trials":756,"activeCount":95},[],{"trials":758,"activeCount":95},[759],{"nctId":760,"briefTitle":761,"status":762,"phases":763,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":769},"NCT03537144","Acetaminophen vs Indomethacin in Treating hsPDA","TERMINATED",[86],"2018-09","2016-06",37,[768],"Patent Ductus Arteriosus",[770,740],"Indomethacin",{"trials":772,"activeCount":95},[],{"trials":774,"activeCount":95},[],{"intervention":776,"totalTrials":333,"cells":777},"Bupivacaine",{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":794,"PHASE3":796,"PHASE4":808,"NA":810},{"trials":779,"activeCount":95},[],{"trials":781,"activeCount":95},[782],{"nctId":783,"briefTitle":784,"status":762,"phases":785,"primaryCompletion":786,"completion":786,"start":787,"enrollment":788,"conditions":789,"interventions":791},"NCT02400645","TAP Block With Liposomal Bupivacaine Versus Pre-incisional Wound Infiltration With Bupivacaine for Postoperative Pain",[84],"2016-05","2015-03",69,[790],"Postoperative Pain",[792,776,793],"Liposomal bupivacaine","Ketorolac",{"trials":795,"activeCount":95},[],{"trials":797,"activeCount":95},[798],{"nctId":799,"briefTitle":800,"status":344,"phases":801,"primaryCompletion":802,"completion":802,"start":803,"enrollment":804,"conditions":805,"interventions":806},"NCT03027661","Para-cervical Block Prior to Laparoscopic Hysterectomy as an Adjuvant Treatment to Reduce Postoperative Pain.",[86],"2018-06-30","2017-08-01",41,[28],[776,807],"0.9% Sodium Chloride",{"trials":809,"activeCount":95},[],{"trials":811,"activeCount":95},[],{"intervention":770,"totalTrials":91,"cells":813},{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":826,"NA":828},{"trials":815,"activeCount":95},[],{"trials":817,"activeCount":95},[],{"trials":819,"activeCount":95},[],{"trials":821,"activeCount":95},[822],{"nctId":760,"briefTitle":761,"status":762,"phases":823,"primaryCompletion":764,"completion":764,"start":765,"enrollment":766,"conditions":824,"interventions":825},[86],[768],[770,740],{"trials":827,"activeCount":95},[],{"trials":829,"activeCount":95},[],{"intervention":807,"totalTrials":91,"cells":831},{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":844,"NA":846},{"trials":833,"activeCount":95},[],{"trials":835,"activeCount":95},[],{"trials":837,"activeCount":95},[],{"trials":839,"activeCount":95},[840],{"nctId":799,"briefTitle":800,"status":344,"phases":841,"primaryCompletion":802,"completion":802,"start":803,"enrollment":804,"conditions":842,"interventions":843},[86],[28],[776,807],{"trials":845,"activeCount":95},[],{"trials":847,"activeCount":95},[],{"intervention":849,"totalTrials":91,"cells":850},"cannabidiol",{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":870,"NA":872},{"trials":852,"activeCount":95},[],{"trials":854,"activeCount":95},[],{"trials":856,"activeCount":95},[],{"trials":858,"activeCount":95},[859],{"nctId":860,"briefTitle":861,"status":344,"phases":862,"primaryCompletion":863,"completion":863,"start":864,"enrollment":865,"conditions":866,"interventions":868},"NCT04271917","Analgesic Effects of Cannabidiol for Simple Tooth Extractions in Dental Patients",[86],"2022-03-31","2020-02-24",68,[867],"Pain, Acute",[849,869],"acetaminophen 500mg and ibuprofen 200mg combo",{"trials":871,"activeCount":95},[],{"trials":873,"activeCount":95},[],{"intervention":869,"totalTrials":91,"cells":875},{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":882,"PHASE4":888,"NA":890},{"trials":877,"activeCount":95},[],{"trials":879,"activeCount":95},[],{"trials":881,"activeCount":95},[],{"trials":883,"activeCount":95},[884],{"nctId":860,"briefTitle":861,"status":344,"phases":885,"primaryCompletion":863,"completion":863,"start":864,"enrollment":865,"conditions":886,"interventions":887},[86],[867],[849,869],{"trials":889,"activeCount":95},[],{"trials":891,"activeCount":95},[],{"intervention":893,"totalTrials":91,"cells":894},"Milnacipran",{"EARLY_PHASE1":895,"PHASE1":897,"PHASE2":899,"PHASE3":901,"PHASE4":913,"NA":915},{"trials":896,"activeCount":95},[],{"trials":898,"activeCount":95},[],{"trials":900,"activeCount":95},[],{"trials":902,"activeCount":95},[903],{"nctId":904,"briefTitle":905,"status":344,"phases":906,"primaryCompletion":907,"completion":907,"start":908,"enrollment":12,"conditions":909,"interventions":912},"NCT01304589","Savella in Treatment for Provoked Vestibulodynia",[86],"2012-09","2010-10",[910,911],"Vestibulodynia","Vulvodynia",[893],{"trials":914,"activeCount":95},[],{"trials":916,"activeCount":95},[],{"intervention":918,"totalTrials":333,"cells":919},"temsirolimus",{"EARLY_PHASE1":920,"PHASE1":922,"PHASE2":924,"PHASE3":948,"PHASE4":950,"NA":952},{"trials":921,"activeCount":95},[],{"trials":923,"activeCount":95},[],{"trials":925,"activeCount":95},[926,938],{"nctId":927,"briefTitle":928,"status":762,"phases":929,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":933,"interventions":935},"NCT01015664","Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",[84,85],"2012-12","2010-02",11,[934],"Squamous Cell Carcinoma of the Head and Neck",[918,936,937],"cisplatin","cetuximab",{"nctId":939,"briefTitle":940,"status":616,"phases":941,"primaryCompletion":930,"completion":942,"start":931,"enrollment":943,"conditions":944,"interventions":946},"NCT01567930","Temsirolimus as Second-line Therapy in HCC",[85],"2013-03",25,[945],"Unresectable or Metastatic Hepatocellular Carcinoma",[947],"Temsirolimus",{"trials":949,"activeCount":95},[],{"trials":951,"activeCount":95},[],{"trials":953,"activeCount":95},[],{"intervention":955,"totalTrials":91,"cells":956},"Oral bovine type II collagen",{"EARLY_PHASE1":957,"PHASE1":959,"PHASE2":961,"PHASE3":973,"PHASE4":975,"NA":977},{"trials":958,"activeCount":95},[],{"trials":960,"activeCount":95},[],{"trials":962,"activeCount":95},[963],{"nctId":964,"briefTitle":965,"status":344,"phases":966,"primaryCompletion":967,"completion":967,"start":968,"enrollment":969,"conditions":970,"interventions":972},"NCT00000401","Oral Collagen for Rheumatoid Arthritis",[85],"2005-08","1999-07",110,[971],"Rheumatoid Arthritis",[955],{"trials":974,"activeCount":95},[],{"trials":976,"activeCount":95},[],{"trials":978,"activeCount":95},[],{"intervention":980,"totalTrials":91,"cells":981},"Bicillin L-A",{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":998,"PHASE4":1000,"NA":1002},{"trials":983,"activeCount":95},[],{"trials":985,"activeCount":95},[],{"trials":987,"activeCount":95},[988],{"nctId":989,"briefTitle":990,"status":762,"phases":991,"primaryCompletion":992,"completion":992,"start":993,"enrollment":994,"conditions":995,"interventions":997},"NCT00427609","Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications",[85],"2009-11","2007-01",5,[996],"Psoriasis",[980],{"trials":999,"activeCount":95},[],{"trials":1001,"activeCount":95},[],{"trials":1003,"activeCount":95},[],{"intervention":1005,"totalTrials":91,"cells":1006},"Ruboxistaurin",{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1022,"PHASE4":1024,"NA":1026},{"trials":1008,"activeCount":95},[],{"trials":1010,"activeCount":95},[],{"trials":1012,"activeCount":95},[1013],{"nctId":1014,"briefTitle":1015,"status":686,"phases":1016,"primaryCompletion":1017,"completion":1017,"start":1018,"enrollment":95,"conditions":1019,"interventions":1021},"NCT02769611","Ruboxistaurin in New York Heart Failure Classification III-IV Patients",[84,85],"2022-01-01","2017-06-28",[1020],"Heart Failure",[1005],{"trials":1023,"activeCount":95},[],{"trials":1025,"activeCount":95},[],{"trials":1027,"activeCount":95},[],{"intervention":1029,"totalTrials":91,"cells":1030},"124I-p5+14",{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1032,"activeCount":95},[],{"trials":1034,"activeCount":95},[],{"trials":1036,"activeCount":95},[1037],{"nctId":1038,"briefTitle":1039,"status":344,"phases":1040,"primaryCompletion":1041,"completion":1041,"start":1042,"enrollment":433,"conditions":1043,"interventions":1045},"NCT03678259","124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis",[84,85],"2021-10-01","2018-10-01",[1044],"Systemic Amyloidosis",[1029],{"trials":1047,"activeCount":95},[],{"trials":1049,"activeCount":95},[],{"trials":1051,"activeCount":95},[],{"intervention":1053,"totalTrials":91,"cells":1054},"Sulfur hexafluoride type-a lipid microspheres",{"EARLY_PHASE1":1055,"PHASE1":1057,"PHASE2":1059,"PHASE3":1072,"PHASE4":1074,"NA":1076},{"trials":1056,"activeCount":95},[],{"trials":1058,"activeCount":95},[],{"trials":1060,"activeCount":95},[1061],{"nctId":1062,"briefTitle":1063,"status":344,"phases":1064,"primaryCompletion":1065,"completion":1065,"start":1066,"enrollment":1067,"conditions":1068,"interventions":1071},"NCT02786810","Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy",[85],"2016-11","2016-03",10,[1069,1070],"Urinary Tract Infection","Vesicoureteral Reflux",[1053],{"trials":1073,"activeCount":95},[],{"trials":1075,"activeCount":95},[],{"trials":1077,"activeCount":95},[],{"intervention":1079,"totalTrials":91,"cells":1080},"Bupivacaine liposome",{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1097,"PHASE4":1099,"NA":1101},{"trials":1082,"activeCount":95},[],{"trials":1084,"activeCount":95},[],{"trials":1086,"activeCount":95},[1087],{"nctId":1088,"briefTitle":1089,"status":616,"phases":1090,"primaryCompletion":1091,"completion":1091,"start":1092,"enrollment":297,"conditions":1093,"interventions":1095},"NCT03560362","Postoperative Pain Control With Lipossomic Extended Release Bupivacaine",[84,85],"2018-10-31","2015-07-09",[28,1094],"Lung Cancer",[1079,1096],"Bupivacaine \u002F Epinephrine",{"trials":1098,"activeCount":95},[],{"trials":1100,"activeCount":95},[],{"trials":1102,"activeCount":95},[],{"intervention":1096,"totalTrials":91,"cells":1104},{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1115,"PHASE4":1117,"NA":1119},{"trials":1106,"activeCount":95},[],{"trials":1108,"activeCount":95},[],{"trials":1110,"activeCount":95},[1111],{"nctId":1088,"briefTitle":1089,"status":616,"phases":1112,"primaryCompletion":1091,"completion":1091,"start":1092,"enrollment":297,"conditions":1113,"interventions":1114},[84,85],[28,1094],[1079,1096],{"trials":1116,"activeCount":95},[],{"trials":1118,"activeCount":95},[],{"trials":1120,"activeCount":95},[],{"intervention":937,"totalTrials":91,"cells":1122},{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1133,"PHASE4":1135,"NA":1137},{"trials":1124,"activeCount":95},[],{"trials":1126,"activeCount":95},[],{"trials":1128,"activeCount":95},[1129],{"nctId":927,"briefTitle":928,"status":762,"phases":1130,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":1131,"interventions":1132},[84,85],[934],[918,936,937],{"trials":1134,"activeCount":95},[],{"trials":1136,"activeCount":95},[],{"trials":1138,"activeCount":95},[],{"intervention":1140,"totalTrials":91,"cells":1141},"methylprednisolone",{"EARLY_PHASE1":1142,"PHASE1":1144,"PHASE2":1146,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1143,"activeCount":95},[],{"trials":1145,"activeCount":95},[],{"trials":1147,"activeCount":95},[1148],{"nctId":1149,"briefTitle":1150,"status":616,"phases":1151,"primaryCompletion":1152,"completion":732,"start":908,"enrollment":1153,"conditions":1154,"interventions":1157},"NCT01274260","Trial of Steroids in Pediatric Acute Lung Injury\u002FARDS",[85],"2014-01",100,[1155,1156],"Acute Respiratory Distress Syndrome (ARDS)","Acute Lung Injury (ALI)",[1140,1158],"Normal Saline",{"trials":1160,"activeCount":95},[],{"trials":1162,"activeCount":95},[],{"trials":1164,"activeCount":95},[],{"intervention":1158,"totalTrials":91,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1171,"PHASE3":1177,"PHASE4":1179,"NA":1181},{"trials":1168,"activeCount":95},[],{"trials":1170,"activeCount":95},[],{"trials":1172,"activeCount":95},[1173],{"nctId":1149,"briefTitle":1150,"status":616,"phases":1174,"primaryCompletion":1152,"completion":732,"start":908,"enrollment":1153,"conditions":1175,"interventions":1176},[85],[1155,1156],[1140,1158],{"trials":1178,"activeCount":95},[],{"trials":1180,"activeCount":95},[],{"trials":1182,"activeCount":95},[],{"intervention":1184,"totalTrials":91,"cells":1185},"Phenobarbital",{"EARLY_PHASE1":1186,"PHASE1":1188,"PHASE2":1190,"PHASE3":1201,"PHASE4":1203,"NA":1205},{"trials":1187,"activeCount":95},[],{"trials":1189,"activeCount":95},[],{"trials":1191,"activeCount":95},[1192],{"nctId":1193,"briefTitle":1194,"status":344,"phases":1195,"primaryCompletion":1196,"completion":1196,"start":1042,"enrollment":943,"conditions":1197,"interventions":1199},"NCT03670160","Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome",[85],"2020-05-31",[1198],"Neonatal Abstinence Syndrome",[1184,1200],"Clonidine",{"trials":1202,"activeCount":95},[],{"trials":1204,"activeCount":95},[],{"trials":1206,"activeCount":95},[],{"intervention":1200,"totalTrials":91,"cells":1208},{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1210,"activeCount":95},[],{"trials":1212,"activeCount":95},[],{"trials":1214,"activeCount":95},[1215],{"nctId":1193,"briefTitle":1194,"status":344,"phases":1216,"primaryCompletion":1196,"completion":1196,"start":1042,"enrollment":943,"conditions":1217,"interventions":1218},[85],[1198],[1184,1200],{"trials":1220,"activeCount":95},[],{"trials":1222,"activeCount":95},[],{"trials":1224,"activeCount":95},[],{"intervention":351,"totalTrials":91,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1237,"PHASE4":1239,"NA":1241},{"trials":1228,"activeCount":95},[],{"trials":1230,"activeCount":95},[],{"trials":1232,"activeCount":95},[1233],{"nctId":342,"briefTitle":343,"status":344,"phases":1234,"completion":346,"start":347,"conditions":1235,"interventions":1236},[85],[349],[351,352,353,354,355],{"trials":1238,"activeCount":95},[],{"trials":1240,"activeCount":95},[],{"trials":1242,"activeCount":95},[],{"intervention":352,"totalTrials":91,"cells":1244},{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1255,"PHASE4":1257,"NA":1259},{"trials":1246,"activeCount":95},[],{"trials":1248,"activeCount":95},[],{"trials":1250,"activeCount":95},[1251],{"nctId":342,"briefTitle":343,"status":344,"phases":1252,"completion":346,"start":347,"conditions":1253,"interventions":1254},[85],[349],[351,352,353,354,355],{"trials":1256,"activeCount":95},[],{"trials":1258,"activeCount":95},[],{"trials":1260,"activeCount":95},[],{"intervention":353,"totalTrials":91,"cells":1262},{"EARLY_PHASE1":1263,"PHASE1":1265,"PHASE2":1267,"PHASE3":1273,"PHASE4":1275,"NA":1277},{"trials":1264,"activeCount":95},[],{"trials":1266,"activeCount":95},[],{"trials":1268,"activeCount":95},[1269],{"nctId":342,"briefTitle":343,"status":344,"phases":1270,"completion":346,"start":347,"conditions":1271,"interventions":1272},[85],[349],[351,352,353,354,355],{"trials":1274,"activeCount":95},[],{"trials":1276,"activeCount":95},[],{"trials":1278,"activeCount":95},[],{"intervention":355,"totalTrials":91,"cells":1280},{"EARLY_PHASE1":1281,"PHASE1":1283,"PHASE2":1285,"PHASE3":1291,"PHASE4":1293,"NA":1295},{"trials":1282,"activeCount":95},[],{"trials":1284,"activeCount":95},[],{"trials":1286,"activeCount":95},[1287],{"nctId":342,"briefTitle":343,"status":344,"phases":1288,"completion":346,"start":347,"conditions":1289,"interventions":1290},[85],[349],[351,352,353,354,355],{"trials":1292,"activeCount":95},[],{"trials":1294,"activeCount":95},[],{"trials":1296,"activeCount":95},[],{"intervention":1298,"totalTrials":91,"cells":1299},"Minocycline",{"EARLY_PHASE1":1300,"PHASE1":1302,"PHASE2":1304,"PHASE3":1316,"PHASE4":1318,"NA":1320},{"trials":1301,"activeCount":95},[],{"trials":1303,"activeCount":95},[],{"trials":1305,"activeCount":95},[1306],{"nctId":1307,"briefTitle":1308,"status":344,"phases":1309,"primaryCompletion":1310,"completion":1310,"start":1311,"enrollment":1312,"conditions":1313,"interventions":1315},"NCT03040128","Use of Minocycline in Intracerebral Hemorrhage",[84,85],"2016-11-30","2013-06-27",20,[1314],"Intracerebral Hemorrhage",[1298],{"trials":1317,"activeCount":95},[],{"trials":1319,"activeCount":95},[],{"trials":1321,"activeCount":95},[],{"intervention":1323,"totalTrials":91,"cells":1324},"amifostine trihydrate",{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1343,"PHASE4":1345,"NA":1347},{"trials":1326,"activeCount":95},[],{"trials":1328,"activeCount":95},[],{"trials":1330,"activeCount":95},[1331],{"nctId":1332,"briefTitle":1333,"status":344,"phases":1334,"completion":1335,"start":1336,"conditions":1337,"interventions":1342},"NCT00003580","Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer",[85],"2004-05","1998-06",[1338,1339,1340,1341],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan","Head and Neck Cancer","Oral Complications","Radiation Toxicity",[1323,936],{"trials":1344,"activeCount":95},[],{"trials":1346,"activeCount":95},[],{"trials":1348,"activeCount":95},[],{"intervention":1350,"totalTrials":91,"cells":1351},"Hydrocortisone",{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1356,"PHASE3":1368,"PHASE4":1370,"NA":1372},{"trials":1353,"activeCount":95},[],{"trials":1355,"activeCount":95},[],{"trials":1357,"activeCount":95},[1358],{"nctId":1359,"briefTitle":1360,"status":344,"phases":1361,"primaryCompletion":1362,"completion":1362,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1367},"NCT03710187","HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients",[85],"2019-09-27","2018-11-05",84,[1366],"Septic Shock",[1350],{"trials":1369,"activeCount":95},[],{"trials":1371,"activeCount":95},[],{"trials":1373,"activeCount":95},[],{"intervention":1375,"totalTrials":91,"cells":1376},"Injection of peptide p5+14 radiolabeled with iodine-124",{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1392,"PHASE4":1394,"NA":1396},{"trials":1378,"activeCount":95},[],{"trials":1380,"activeCount":95},[],{"trials":1382,"activeCount":95},[1383],{"nctId":1384,"briefTitle":1385,"status":344,"phases":1386,"primaryCompletion":1387,"completion":1388,"start":1389,"enrollment":556,"conditions":1390,"interventions":1391},"NCT05968846","Repeat PET\u002FCT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load",[85],"2023-08-01","2023-09-01","2022-12-07",[1044],[1375],{"trials":1393,"activeCount":95},[],{"trials":1395,"activeCount":95},[],{"trials":1397,"activeCount":95},[],{"intervention":1399,"totalTrials":91,"cells":1400},"Human immune globulin intravenous",{"EARLY_PHASE1":1401,"PHASE1":1403,"PHASE2":1405,"PHASE3":1417,"PHASE4":1419,"NA":1421},{"trials":1402,"activeCount":95},[],{"trials":1404,"activeCount":95},[],{"trials":1406,"activeCount":95},[1407],{"nctId":1408,"briefTitle":1409,"status":344,"phases":1410,"primaryCompletion":1411,"completion":1411,"start":1412,"enrollment":1067,"conditions":1413,"interventions":1416},"NCT00547365","Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction",[84,85],"2011-07","2007-10",[1414,1415],"Multiple Myeloma","Plasma Cell Neoplasm",[1399],{"trials":1418,"activeCount":95},[],{"trials":1420,"activeCount":95},[],{"trials":1422,"activeCount":95},[],{"intervention":1424,"totalTrials":91,"cells":1425},"Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim",{"EARLY_PHASE1":1426,"PHASE1":1428,"PHASE2":1430,"PHASE3":1441,"PHASE4":1443,"NA":1445},{"trials":1427,"activeCount":95},[],{"trials":1429,"activeCount":95},[],{"trials":1431,"activeCount":95},[1432],{"nctId":1433,"briefTitle":1434,"status":616,"phases":1435,"primaryCompletion":1436,"completion":664,"start":1437,"enrollment":621,"conditions":1438,"interventions":1440},"NCT00777673","Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.",[85],"2013-01","2008-10",[1439],"Breast Cancer",[1424],{"trials":1442,"activeCount":95},[],{"trials":1444,"activeCount":95},[],{"trials":1446,"activeCount":95},[],{"intervention":1448,"totalTrials":333,"cells":1449},"124I-labeled monoclonal antibody Mu 11-1F4",{"EARLY_PHASE1":1450,"PHASE1":1452,"PHASE2":1472,"PHASE3":1474,"PHASE4":1476,"NA":1478},{"trials":1451,"activeCount":95},[],{"trials":1453,"activeCount":95},[1454,1464],{"nctId":1455,"briefTitle":1456,"status":344,"phases":1457,"primaryCompletion":1458,"completion":1459,"start":1460,"enrollment":319,"conditions":1461,"interventions":1463},"NCT00807872","Radioimmunoimaging of AL Amyloidosis",[84],"2012-03","2013-07","2008-12",[1462],"Primary Amyloidosis",[1448],{"nctId":1465,"briefTitle":1456,"status":344,"phases":1466,"primaryCompletion":1458,"completion":1458,"start":1467,"enrollment":1468,"conditions":1469,"interventions":1471},"NCT01409148",[84],"2008-11",38,[1470],"AL Amyloidosis",[1448],{"trials":1473,"activeCount":95},[],{"trials":1475,"activeCount":95},[],{"trials":1477,"activeCount":95},[],{"trials":1479,"activeCount":95},[],{"intervention":1481,"totalTrials":91,"cells":1482},"18F-AraG",{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1496,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1484,"activeCount":95},[],{"trials":1486,"activeCount":95},[1487],{"nctId":1488,"briefTitle":1489,"status":616,"phases":1490,"primaryCompletion":1491,"completion":1491,"start":1492,"enrollment":333,"conditions":1493,"interventions":1495},"NCT04052412","Biodistribution and Kinetics of 18F-AraG in Non-Small Cell Lung Cancer",[84],"2023-12-31","2019-07-16",[1494],"Non-small Cell Lung Cancer",[1481],{"trials":1497,"activeCount":95},[],{"trials":1499,"activeCount":95},[],{"trials":1501,"activeCount":95},[],{"trials":1503,"activeCount":95},[],{"intervention":1505,"totalTrials":91,"cells":1506},"Ethanol",{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1522,"PHASE3":1524,"PHASE4":1526,"NA":1528},{"trials":1508,"activeCount":95},[],{"trials":1510,"activeCount":95},[1511],{"nctId":1512,"briefTitle":1513,"status":344,"phases":1514,"primaryCompletion":1515,"completion":1515,"start":1516,"enrollment":556,"conditions":1517,"interventions":1519},"NCT01708369","Alcohol Inhibits Drug Metabolism by Carboxylesterases",[84],"2012-05","2012-02",[1518],"Drug Interactions",[1505,1520,1521],"Oseltamivir","Aspirin",{"trials":1523,"activeCount":95},[],{"trials":1525,"activeCount":95},[],{"trials":1527,"activeCount":95},[],{"trials":1529,"activeCount":95},[],{"intervention":1520,"totalTrials":91,"cells":1531},{"EARLY_PHASE1":1532,"PHASE1":1534,"PHASE2":1540,"PHASE3":1542,"PHASE4":1544,"NA":1546},{"trials":1533,"activeCount":95},[],{"trials":1535,"activeCount":95},[1536],{"nctId":1512,"briefTitle":1513,"status":344,"phases":1537,"primaryCompletion":1515,"completion":1515,"start":1516,"enrollment":556,"conditions":1538,"interventions":1539},[84],[1518],[1505,1520,1521],{"trials":1541,"activeCount":95},[],{"trials":1543,"activeCount":95},[],{"trials":1545,"activeCount":95},[],{"trials":1547,"activeCount":95},[],{"intervention":1521,"totalTrials":91,"cells":1549},{"EARLY_PHASE1":1550,"PHASE1":1552,"PHASE2":1558,"PHASE3":1560,"PHASE4":1562,"NA":1564},{"trials":1551,"activeCount":95},[],{"trials":1553,"activeCount":95},[1554],{"nctId":1512,"briefTitle":1513,"status":344,"phases":1555,"primaryCompletion":1515,"completion":1515,"start":1516,"enrollment":556,"conditions":1556,"interventions":1557},[84],[1518],[1505,1520,1521],{"trials":1559,"activeCount":95},[],{"trials":1561,"activeCount":95},[],{"trials":1563,"activeCount":95},[],{"trials":1565,"activeCount":95},[],{"intervention":1567,"totalTrials":91,"cells":1568},"ursodeoxycholic acid",{"EARLY_PHASE1":1569,"PHASE1":1571,"PHASE2":1583,"PHASE3":1585,"PHASE4":1587,"NA":1589},{"trials":1570,"activeCount":95},[],{"trials":1572,"activeCount":95},[1573],{"nctId":1574,"briefTitle":1575,"status":344,"phases":1576,"primaryCompletion":1577,"completion":1578,"start":908,"enrollment":1579,"conditions":1580,"interventions":1582},"NCT01088607","Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis",[84],"2016-12","2017-06",27,[1581],"Primary Sclerosing Cholangitis",[1567],{"trials":1584,"activeCount":95},[],{"trials":1586,"activeCount":95},[],{"trials":1588,"activeCount":95},[],{"trials":1590,"activeCount":95},[],{"intervention":792,"totalTrials":91,"cells":1592},{"EARLY_PHASE1":1593,"PHASE1":1595,"PHASE2":1601,"PHASE3":1603,"PHASE4":1605,"NA":1607},{"trials":1594,"activeCount":95},[],{"trials":1596,"activeCount":95},[1597],{"nctId":783,"briefTitle":784,"status":762,"phases":1598,"primaryCompletion":786,"completion":786,"start":787,"enrollment":788,"conditions":1599,"interventions":1600},[84],[790],[792,776,793],{"trials":1602,"activeCount":95},[],{"trials":1604,"activeCount":95},[],{"trials":1606,"activeCount":95},[],{"trials":1608,"activeCount":95},[],{"intervention":793,"totalTrials":91,"cells":1610},{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1612,"activeCount":95},[],{"trials":1614,"activeCount":95},[1615],{"nctId":783,"briefTitle":784,"status":762,"phases":1616,"primaryCompletion":786,"completion":786,"start":787,"enrollment":788,"conditions":1617,"interventions":1618},[84],[790],[792,776,793],{"trials":1620,"activeCount":95},[],{"trials":1622,"activeCount":95},[],{"trials":1624,"activeCount":95},[],{"trials":1626,"activeCount":95},[],{"intervention":1628,"totalTrials":91,"cells":1629},"Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1641,"PHASE3":1643,"PHASE4":1645,"NA":1647},{"trials":1631,"activeCount":95},[],{"trials":1633,"activeCount":95},[1634],{"nctId":1635,"briefTitle":1636,"status":344,"phases":1637,"primaryCompletion":1459,"completion":1459,"start":1460,"enrollment":1638,"conditions":1639,"interventions":1640},"NCT01815086","Radioimmunoimaging of Light Chain (AL) Amyloidosis",[84],30,[1470],[1628],{"trials":1642,"activeCount":95},[],{"trials":1644,"activeCount":95},[],{"trials":1646,"activeCount":95},[],{"trials":1648,"activeCount":95},[],{"intervention":1650,"totalTrials":91,"cells":1651},"magnesium",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1666,"PHASE3":1668,"PHASE4":1670,"NA":1672},{"trials":1653,"activeCount":95},[],{"trials":1655,"activeCount":95},[1656],{"nctId":1657,"briefTitle":1658,"status":344,"phases":1659,"completion":1660,"start":1661,"enrollment":1662,"conditions":1663,"interventions":1665},"NCT00346658","Magnesium Supplementation to Prevent Bone Loss",[84],"2006-09","2002-07",74,[1664],"Osteoporosis",[1650],{"trials":1667,"activeCount":95},[],{"trials":1669,"activeCount":95},[],{"trials":1671,"activeCount":95},[],{"trials":1673,"activeCount":95},[],{"intervention":1675,"totalTrials":91,"cells":1676},"99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m.",{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1690,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1678,"activeCount":95},[],{"trials":1680,"activeCount":95},[1681],{"nctId":1682,"briefTitle":1683,"status":616,"phases":1684,"primaryCompletion":1685,"completion":46,"start":1686,"enrollment":407,"conditions":1687,"interventions":1688},"NCT05951816","A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis",[84],"2024-12","2023-07",[1044],[1675,1689],"99mTc-Pyrophosphate and 99mtc-p5+14 - an Amyloid Reactive Peptide Labeled With Technetium-99m.",{"trials":1691,"activeCount":95},[],{"trials":1693,"activeCount":95},[],{"trials":1695,"activeCount":95},[],{"trials":1697,"activeCount":95},[],{"intervention":1689,"totalTrials":91,"cells":1699},{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1708,"PHASE3":1710,"PHASE4":1712,"NA":1714},{"trials":1701,"activeCount":95},[],{"trials":1703,"activeCount":95},[1704],{"nctId":1682,"briefTitle":1683,"status":616,"phases":1705,"primaryCompletion":1685,"completion":46,"start":1686,"enrollment":407,"conditions":1706,"interventions":1707},[84],[1044],[1675,1689],{"trials":1709,"activeCount":95},[],{"trials":1711,"activeCount":95},[],{"trials":1713,"activeCount":95},[],{"trials":1715,"activeCount":95},[],{"intervention":1717,"totalTrials":91,"cells":1718},"Labetalol Hydrochloride 200 mg",{"EARLY_PHASE1":1719,"PHASE1":1734,"PHASE2":1736,"PHASE3":1738,"PHASE4":1740,"NA":1742},{"trials":1720,"activeCount":95},[1721],{"nctId":1722,"briefTitle":1723,"status":616,"phases":1724,"primaryCompletion":1725,"completion":1726,"start":1727,"enrollment":1728,"conditions":1729,"interventions":1731},"NCT03105661","Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients",[83],"2019-12-31","2020-03-04","2017-04-04",400,[1730,22],"Obesity, Morbid",[1717,1732,1733],"NIFEdipine 60 mg","Atenolol 25 mg",{"trials":1735,"activeCount":95},[],{"trials":1737,"activeCount":95},[],{"trials":1739,"activeCount":95},[],{"trials":1741,"activeCount":95},[],{"trials":1743,"activeCount":95},[],{"intervention":1732,"totalTrials":91,"cells":1745},{"EARLY_PHASE1":1746,"PHASE1":1752,"PHASE2":1754,"PHASE3":1756,"PHASE4":1758,"NA":1760},{"trials":1747,"activeCount":95},[1748],{"nctId":1722,"briefTitle":1723,"status":616,"phases":1749,"primaryCompletion":1725,"completion":1726,"start":1727,"enrollment":1728,"conditions":1750,"interventions":1751},[83],[1730,22],[1717,1732,1733],{"trials":1753,"activeCount":95},[],{"trials":1755,"activeCount":95},[],{"trials":1757,"activeCount":95},[],{"trials":1759,"activeCount":95},[],{"trials":1761,"activeCount":95},[],{"intervention":1733,"totalTrials":91,"cells":1763},{"EARLY_PHASE1":1764,"PHASE1":1770,"PHASE2":1772,"PHASE3":1774,"PHASE4":1776,"NA":1778},{"trials":1765,"activeCount":95},[1766],{"nctId":1722,"briefTitle":1723,"status":616,"phases":1767,"primaryCompletion":1725,"completion":1726,"start":1727,"enrollment":1728,"conditions":1768,"interventions":1769},[83],[1730,22],[1717,1732,1733],{"trials":1771,"activeCount":95},[],{"trials":1773,"activeCount":95},[],{"trials":1775,"activeCount":95},[],{"trials":1777,"activeCount":95},[],{"trials":1779,"activeCount":95},[],{"intervention":1781,"totalTrials":91,"cells":1782},"Labetalol Hydrocholoride 200 mg orally every 12 hours",{"EARLY_PHASE1":1783,"PHASE1":1796,"PHASE2":1798,"PHASE3":1800,"PHASE4":1802,"NA":1804},{"trials":1784,"activeCount":95},[1785],{"nctId":1786,"briefTitle":1787,"status":686,"phases":1788,"primaryCompletion":1789,"completion":1789,"start":1790,"enrollment":95,"conditions":1791,"interventions":1793},"NCT03245970","Impedance Cardiography to Decrease the Risk of Preeclampsia",[83],"2020-02-29","2017-04-24",[1792,22],"Chronic Hypertension Complicating Pregnancy (Diagnosis)",[1781,1794,1795],"Nifedipine 60 mg orally daily","Atenolol 25 mg daily",{"trials":1797,"activeCount":95},[],{"trials":1799,"activeCount":95},[],{"trials":1801,"activeCount":95},[],{"trials":1803,"activeCount":95},[],{"trials":1805,"activeCount":95},[],{"intervention":1794,"totalTrials":91,"cells":1807},{"EARLY_PHASE1":1808,"PHASE1":1814,"PHASE2":1816,"PHASE3":1818,"PHASE4":1820,"NA":1822},{"trials":1809,"activeCount":95},[1810],{"nctId":1786,"briefTitle":1787,"status":686,"phases":1811,"primaryCompletion":1789,"completion":1789,"start":1790,"enrollment":95,"conditions":1812,"interventions":1813},[83],[1792,22],[1781,1794,1795],{"trials":1815,"activeCount":95},[],{"trials":1817,"activeCount":95},[],{"trials":1819,"activeCount":95},[],{"trials":1821,"activeCount":95},[],{"trials":1823,"activeCount":95},[],{"intervention":1795,"totalTrials":91,"cells":1825},{"EARLY_PHASE1":1826,"PHASE1":1832,"PHASE2":1834,"PHASE3":1836,"PHASE4":1838,"NA":1840},{"trials":1827,"activeCount":95},[1828],{"nctId":1786,"briefTitle":1787,"status":686,"phases":1829,"primaryCompletion":1789,"completion":1789,"start":1790,"enrollment":95,"conditions":1830,"interventions":1831},[83],[1792,22],[1781,1794,1795],{"trials":1833,"activeCount":95},[],{"trials":1835,"activeCount":95},[],{"trials":1837,"activeCount":95},[],{"trials":1839,"activeCount":95},[],{"trials":1841,"activeCount":95},[],{"intervention":936,"totalTrials":26,"cells":1843},{"EARLY_PHASE1":1844,"PHASE1":1846,"PHASE2":1848,"PHASE3":1858,"PHASE4":1860,"NA":1862},{"trials":1845,"activeCount":95},[],{"trials":1847,"activeCount":95},[],{"trials":1849,"activeCount":95},[1850,1854],{"nctId":927,"briefTitle":928,"status":762,"phases":1851,"primaryCompletion":930,"completion":930,"start":931,"enrollment":932,"conditions":1852,"interventions":1853},[84,85],[934],[918,936,937],{"nctId":1332,"briefTitle":1333,"status":344,"phases":1855,"completion":1335,"start":1336,"conditions":1856,"interventions":1857},[85],[1338,1339,1340,1341],[1323,936],{"trials":1859,"activeCount":95},[],{"trials":1861,"activeCount":95},[],{"trials":1863,"activeCount":95},[1864],{"nctId":1865,"briefTitle":1866,"status":686,"phases":1867,"enrollment":621,"conditions":1868,"interventions":1870},"NCT00347256","Chemoradiotherapy Followed by Surgery for Advanced Paranasal Sinus Cancer",[88],[1869],"Paranasal Sinus Neoplasms",[936],{"intervention":1872,"totalTrials":333,"cells":1873},"Vancomycin",{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1878,"PHASE3":1880,"PHASE4":1882,"NA":1893},{"trials":1875,"activeCount":95},[],{"trials":1877,"activeCount":95},[],{"trials":1879,"activeCount":95},[],{"trials":1881,"activeCount":95},[],{"trials":1883,"activeCount":95},[1884],{"nctId":1885,"briefTitle":1886,"status":762,"phases":1887,"primaryCompletion":1888,"completion":1888,"start":787,"enrollment":932,"conditions":1889,"interventions":1892},"NCT02400112","Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures",[87],"2018-10",[1890,1891],"Fractures, Open","Surgical Wound Infection",[1872],{"trials":1894,"activeCount":95},[1895],{"nctId":1896,"briefTitle":1897,"status":762,"phases":1898,"primaryCompletion":1899,"completion":731,"start":1900,"enrollment":1901,"conditions":1902,"interventions":1905},"NCT02027532","Prevention of Infection in Closed Fractures: Cefazolin Versus Vancomycin",[88],"2015-06","2009-10",430,[1903,1904],"Infection","Closed Fractures",[1906,1872],"Cefazolin",{"intervention":1908,"totalTrials":333,"cells":1909},"Nicotine Patch",{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1914,"PHASE3":1916,"PHASE4":1918,"NA":1920},{"trials":1911,"activeCount":95},[],{"trials":1913,"activeCount":95},[],{"trials":1915,"activeCount":95},[],{"trials":1917,"activeCount":95},[],{"trials":1919,"activeCount":95},[],{"trials":1921,"activeCount":95},[1922,1931],{"nctId":1923,"briefTitle":1924,"status":344,"phases":1925,"primaryCompletion":1460,"completion":1460,"start":346,"enrollment":1926,"conditions":1927,"interventions":1929},"NCT00308763","Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals",[88],594,[1928],"Tobacco Use Disorder",[1908,1930],"Sustained Release Bupropion",{"nctId":1932,"briefTitle":1933,"status":344,"phases":1934,"primaryCompletion":1935,"completion":1935,"start":1936,"enrollment":1937,"conditions":1938,"interventions":1940},"NCT00632411","Evaluating a Telephone-Based Smoking Cessation Program Among People in the Military (The AFIII Study)",[88],"2014-07","2008-04",1298,[1939,25],"Smoking",[1908],{"intervention":1930,"totalTrials":91,"cells":1942},{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1949,"PHASE4":1951,"NA":1953},{"trials":1944,"activeCount":95},[],{"trials":1946,"activeCount":95},[],{"trials":1948,"activeCount":95},[],{"trials":1950,"activeCount":95},[],{"trials":1952,"activeCount":95},[],{"trials":1954,"activeCount":95},[1955],{"nctId":1923,"briefTitle":1924,"status":344,"phases":1956,"primaryCompletion":1460,"completion":1460,"start":346,"enrollment":1926,"conditions":1957,"interventions":1958},[88],[1928],[1908,1930],{"intervention":1906,"totalTrials":91,"cells":1960},{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1965,"PHASE3":1967,"PHASE4":1969,"NA":1971},{"trials":1962,"activeCount":95},[],{"trials":1964,"activeCount":95},[],{"trials":1966,"activeCount":95},[],{"trials":1968,"activeCount":95},[],{"trials":1970,"activeCount":95},[],{"trials":1972,"activeCount":95},[1973],{"nctId":1896,"briefTitle":1897,"status":762,"phases":1974,"primaryCompletion":1899,"completion":731,"start":1900,"enrollment":1901,"conditions":1975,"interventions":1976},[88],[1903,1904],[1906,1872],{"intervention":1978,"totalTrials":91,"cells":1979},"Exparel",{"EARLY_PHASE1":1980,"PHASE1":1982,"PHASE2":1984,"PHASE3":1986,"PHASE4":1988,"NA":1990},{"trials":1981,"activeCount":95},[],{"trials":1983,"activeCount":95},[],{"trials":1985,"activeCount":95},[],{"trials":1987,"activeCount":95},[],{"trials":1989,"activeCount":95},[],{"trials":1991,"activeCount":95},[1992],{"nctId":1993,"briefTitle":1994,"status":616,"phases":1995,"primaryCompletion":1996,"completion":1996,"start":1997,"enrollment":1998,"conditions":1999,"interventions":2000},"NCT02052180","Early Post-Operative Pain Control Following Wrist Operations",[88],"2014-05","2013-05",70,[36],[1978,2001],"Marcaine",{"intervention":2001,"totalTrials":91,"cells":2003},{"EARLY_PHASE1":2004,"PHASE1":2006,"PHASE2":2008,"PHASE3":2010,"PHASE4":2012,"NA":2014},{"trials":2005,"activeCount":95},[],{"trials":2007,"activeCount":95},[],{"trials":2009,"activeCount":95},[],{"trials":2011,"activeCount":95},[],{"trials":2013,"activeCount":95},[],{"trials":2015,"activeCount":95},[2016],{"nctId":1993,"briefTitle":1994,"status":616,"phases":2017,"primaryCompletion":1996,"completion":1996,"start":1997,"enrollment":1998,"conditions":2018,"interventions":2019},[88],[36],[1978,2001],{"intervention":2021,"totalTrials":91,"cells":2022},"Lidocaine",{"EARLY_PHASE1":2023,"PHASE1":2025,"PHASE2":2027,"PHASE3":2029,"PHASE4":2031,"NA":2033},{"trials":2024,"activeCount":95},[],{"trials":2026,"activeCount":95},[],{"trials":2028,"activeCount":95},[],{"trials":2030,"activeCount":95},[],{"trials":2032,"activeCount":95},[],{"trials":2034,"activeCount":95},[2035],{"nctId":2036,"briefTitle":2037,"status":616,"phases":2038,"primaryCompletion":907,"completion":930,"start":2039,"enrollment":2040,"conditions":2041,"interventions":2043},"NCT01192490","Topical Lidocaine on the Cervix and Intra-Cervical Prior to Insertion of Intrauterine Devices",[88],"2010-08",210,[2042],"Contraception",[2021,2044],"Lubricant",{"intervention":2044,"totalTrials":91,"cells":2046},{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2053,"PHASE4":2055,"NA":2057},{"trials":2048,"activeCount":95},[],{"trials":2050,"activeCount":95},[],{"trials":2052,"activeCount":95},[],{"trials":2054,"activeCount":95},[],{"trials":2056,"activeCount":95},[],{"trials":2058,"activeCount":95},[2059],{"nctId":2036,"briefTitle":2037,"status":616,"phases":2060,"primaryCompletion":907,"completion":930,"start":2039,"enrollment":2040,"conditions":2061,"interventions":2062},[88],[2042],[2021,2044],{"intervention":2064,"totalTrials":91,"cells":2065},"RSI sedation with etomidate\u002Fsuccinylcholine",{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2070,"PHASE3":2072,"PHASE4":2074,"NA":2076},{"trials":2067,"activeCount":95},[],{"trials":2069,"activeCount":95},[],{"trials":2071,"activeCount":95},[],{"trials":2073,"activeCount":95},[],{"trials":2075,"activeCount":95},[],{"trials":2077,"activeCount":95},[2078],{"nctId":2079,"briefTitle":2080,"status":344,"phases":2081,"primaryCompletion":2082,"completion":1660,"start":2083,"enrollment":1638,"conditions":2084,"interventions":2086},"NCT00462644","Evaluation of Etomidate on Adrenal Function in Trauma Patients",[88],"2006-08","2006-02",[2085],"Adrenal Insufficiency",[2064,2087],"RSI sedation with fentanyl\u002Fmidazolam\u002Fsuccinylcholine",{"intervention":2087,"totalTrials":91,"cells":2089},{"EARLY_PHASE1":2090,"PHASE1":2092,"PHASE2":2094,"PHASE3":2096,"PHASE4":2098,"NA":2100},{"trials":2091,"activeCount":95},[],{"trials":2093,"activeCount":95},[],{"trials":2095,"activeCount":95},[],{"trials":2097,"activeCount":95},[],{"trials":2099,"activeCount":95},[],{"trials":2101,"activeCount":95},[2102],{"nctId":2079,"briefTitle":2080,"status":344,"phases":2103,"primaryCompletion":2082,"completion":1660,"start":2083,"enrollment":1638,"conditions":2104,"interventions":2105},[88],[2085],[2064,2087],{"intervention":2107,"totalTrials":91,"cells":2108},"Ropivacaine",{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2113,"PHASE3":2115,"PHASE4":2117,"NA":2119},{"trials":2110,"activeCount":95},[],{"trials":2112,"activeCount":95},[],{"trials":2114,"activeCount":95},[],{"trials":2116,"activeCount":95},[],{"trials":2118,"activeCount":95},[],{"trials":2120,"activeCount":95},[2121],{"nctId":2122,"briefTitle":2123,"status":686,"phases":2124,"primaryCompletion":2125,"completion":2126,"start":2127,"enrollment":95,"conditions":2128,"interventions":2132},"NCT04118777","Postoperative Narcotic Use After Laparoscopic Gynecologic Surgery",[88],"2020-06-30","2020-07-30","2020-05-01",[2129,2130,2131],"Pelvic Pain","Endometriosis","Pelvic Prolapse",[2107],{"intervention":2134,"totalTrials":91,"cells":2135},"Lovaza",{"EARLY_PHASE1":2136,"PHASE1":2138,"PHASE2":2140,"PHASE3":2142,"PHASE4":2144,"NA":2146},{"trials":2137,"activeCount":95},[],{"trials":2139,"activeCount":95},[],{"trials":2141,"activeCount":95},[],{"trials":2143,"activeCount":95},[],{"trials":2145,"activeCount":95},[],{"trials":2147,"activeCount":95},[2148],{"nctId":2149,"briefTitle":2150,"status":616,"phases":2151,"primaryCompletion":529,"completion":732,"start":1437,"enrollment":1153,"conditions":2152,"interventions":2154},"NCT01157780","Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation",[88],[2153],"Parenteral Nutrition Associated Liver Disease",[2134],{"intervention":2156,"totalTrials":91,"cells":2157},"Sibutramine",{"EARLY_PHASE1":2158,"PHASE1":2160,"PHASE2":2162,"PHASE3":2164,"PHASE4":2166,"NA":2168},{"trials":2159,"activeCount":95},[],{"trials":2161,"activeCount":95},[],{"trials":2163,"activeCount":95},[],{"trials":2165,"activeCount":95},[],{"trials":2167,"activeCount":95},[],{"trials":2169,"activeCount":95},[2170],{"nctId":2171,"briefTitle":2172,"status":344,"phases":2173,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":2176,"conditions":2177,"interventions":2178},"NCT00037752","Sibutramine to Reduce Weight Gain and Improve Smoking Cessation Rates",[88],"2008-08","2002-09",436,[32,34,19],[2156],{"intervention":2180,"totalTrials":91,"cells":2181},"Formoterol",{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2188,"PHASE4":2190,"NA":2192},{"trials":2183,"activeCount":95},[],{"trials":2185,"activeCount":95},[],{"trials":2187,"activeCount":95},[],{"trials":2189,"activeCount":95},[],{"trials":2191,"activeCount":95},[],{"trials":2193,"activeCount":95},[2194],{"nctId":2195,"briefTitle":2196,"status":344,"phases":2197,"primaryCompletion":1066,"completion":1066,"start":2198,"enrollment":2199,"conditions":2200,"interventions":2201},"NCT02291016","COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers",[88],"2015-02",7,[623],[2180],{"intervention":2203,"totalTrials":91,"cells":2204},"lactulose:mannitol (L:M) oral challenge",{"EARLY_PHASE1":2205,"PHASE1":2207,"PHASE2":2209,"PHASE3":2211,"PHASE4":2213,"NA":2215},{"trials":2206,"activeCount":95},[],{"trials":2208,"activeCount":95},[],{"trials":2210,"activeCount":95},[],{"trials":2212,"activeCount":95},[],{"trials":2214,"activeCount":95},[],{"trials":2216,"activeCount":95},[2217],{"nctId":2218,"briefTitle":2219,"status":344,"phases":2220,"primaryCompletion":2221,"completion":2221,"start":2222,"enrollment":2223,"conditions":2224,"interventions":2225},"NCT03042923","Intestinal Permeability and Endometriosis",[],"2019-06","2016-04",46,[2130],[2203],{"intervention":2227,"totalTrials":91,"cells":2228},"Tranexamic Acid",{"EARLY_PHASE1":2229,"PHASE1":2231,"PHASE2":2233,"PHASE3":2235,"PHASE4":2237,"NA":2239},{"trials":2230,"activeCount":95},[],{"trials":2232,"activeCount":95},[],{"trials":2234,"activeCount":95},[],{"trials":2236,"activeCount":95},[],{"trials":2238,"activeCount":95},[],{"trials":2240,"activeCount":95},[2241],{"nctId":2242,"briefTitle":2243,"status":616,"phases":2244,"primaryCompletion":2245,"completion":2245,"start":1515,"enrollment":2246,"conditions":2247,"interventions":2252},"NCT02080494","Tranexamic Acid in Orthopaedic Trauma Surgery",[88],"2018-12",101,[2248,2249,2250,2251],"Blood Loss","Trauma","Fracture","Surgery",[2227],{"intervention":2254,"totalTrials":91,"cells":2255},"Gabapentin",{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2260,"PHASE3":2262,"PHASE4":2264,"NA":2266},{"trials":2257,"activeCount":95},[],{"trials":2259,"activeCount":95},[],{"trials":2261,"activeCount":95},[],{"trials":2263,"activeCount":95},[],{"trials":2265,"activeCount":95},[],{"trials":2267,"activeCount":95},[2268],{"nctId":2269,"briefTitle":2270,"status":344,"phases":2271,"primaryCompletion":457,"completion":457,"start":2272,"enrollment":2273,"conditions":2274,"interventions":2275},"NCT01301001","A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response",[88],"2012-08",230,[911],[2254],{"intervention":2277,"totalTrials":91,"cells":2278},"Low-Molecular-Weight Heparin",{"EARLY_PHASE1":2279,"PHASE1":2281,"PHASE2":2283,"PHASE3":2285,"PHASE4":2287,"NA":2289},{"trials":2280,"activeCount":95},[],{"trials":2282,"activeCount":95},[],{"trials":2284,"activeCount":95},[],{"trials":2286,"activeCount":95},[],{"trials":2288,"activeCount":95},[],{"trials":2290,"activeCount":95},[2291],{"nctId":2292,"briefTitle":2293,"status":616,"phases":2294,"primaryCompletion":2295,"completion":2295,"start":931,"enrollment":1153,"conditions":2296,"interventions":2298},"NCT01029821","Low-Molecular-Weight Heparin (LMWH) for Deep Venous Thrombosis (DVT) Prophylaxis",[88],"2013-12",[2297],"Deep Venous Thrombosis",[2277],{"intervention":2300,"totalTrials":91,"cells":2301},"brachial plexus anesthesia",{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2306,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2303,"activeCount":95},[],{"trials":2305,"activeCount":95},[],{"trials":2307,"activeCount":95},[],{"trials":2309,"activeCount":95},[],{"trials":2311,"activeCount":95},[],{"trials":2313,"activeCount":95},[2314],{"nctId":2315,"briefTitle":2316,"status":616,"phases":2317,"primaryCompletion":1725,"completion":1725,"start":2318,"enrollment":1638,"conditions":2319,"interventions":2322},"NCT03592901","Phantom Limb Experience After Brachial Plexus Anesthesia",[],"2016-08-08",[2320,2321],"Phantom Limb","Brachial Plexus Block",[2300],{"intervention":2324,"totalTrials":91,"cells":2325},"Chlorhexidine, Mupirocin",{"EARLY_PHASE1":2326,"PHASE1":2328,"PHASE2":2330,"PHASE3":2332,"PHASE4":2334,"NA":2336},{"trials":2327,"activeCount":95},[],{"trials":2329,"activeCount":95},[],{"trials":2331,"activeCount":95},[],{"trials":2333,"activeCount":95},[],{"trials":2335,"activeCount":95},[],{"trials":2337,"activeCount":95},[2338],{"nctId":2339,"briefTitle":2340,"status":344,"phases":2341,"primaryCompletion":1152,"completion":2342,"start":2343,"enrollment":2344,"conditions":2345,"interventions":2347},"NCT01820455","MRSA in a Trauma Population: Does Decolonization Prevent Infection?",[88],"2014-03","2012-01",55,[2346],"MRSA Colonization",[2324,2348],"Soap baths, Lubricating Jelly",{"intervention":2348,"totalTrials":91,"cells":2350},{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2357,"PHASE4":2359,"NA":2361},{"trials":2352,"activeCount":95},[],{"trials":2354,"activeCount":95},[],{"trials":2356,"activeCount":95},[],{"trials":2358,"activeCount":95},[],{"trials":2360,"activeCount":95},[],{"trials":2362,"activeCount":95},[2363],{"nctId":2339,"briefTitle":2340,"status":344,"phases":2364,"primaryCompletion":1152,"completion":2342,"start":2343,"enrollment":2344,"conditions":2365,"interventions":2366},[88],[2346],[2324,2348]]